TIDMHZD
RNS Number : 4872P
Horizon Discovery Group plc
31 August 2017
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS
RESTRICTED AND, SUBJECT TO CERTAIN EXCEPTIONS, IS NOT FOR RELEASE,
PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY IN, OR INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA
(EXCEPT IN COMPLIANCE WITH CANADIAN SECURITIES LAWS), JAPAN, NEW
ZEALAND, THE REPUBLIC OF IRELAND OR THE REPUBLIC OF SOUTH AFRICA OR
ANY OTHER JURISDICTION IN WHICH THE SAME WOULD BE UNLAWFUL.
FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND
SHALL NOT CONSTITUTE AN OFFER TO SELL OR ISSUE OR THE SOLICITATION
TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE ANY ORDINARY SHARES OF
HORIZON IN ANY JURISDICTION IN WHICH ANY SUCH OFFER OR SOLICITATION
WOULD BE UNLAWFUL. THIS ANNOUNCEMENT SHOULD BE READ IN ITS
ENTIRETY.
THE SECURITIES REFERRED TO HEREIN MAY NOT BE OFFERED OR SOLD IN
THE UNITED STATES ABSENT REGISTRATION OR AN EXEMPTION FROM
REGISTRATION UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED. THE
COMPANY DOES NOT INTEND TO REGISTER ANY OF THE SECURITIES IN THE
UNITED STATES OR TO CONDUCT A PUBLIC OFFERING OF THE SECURITIES IN
THE UNITED STATES.
Horizon Discovery Group plc ("Horizon" or the "Company")
Completion of Acquisition
Cambridge, UK, 31 August 2017: Horizon Discovery Group plc (LSE:
HZD) ("Horizon" or "the Company") is pleased to announce that,
further to the Company's announcement on 22 August 2017, the
acquisition of GE Healthcare Dharmacon, Inc. ("Dharmacon")
completed today and the admission to trading on AIM of the
13,064,868 new ordinary shares of 1 pence each (the "Consideration
Shares") is expected to take place at 8.00 a.m. on 1 September
2017.
Dr. Darrin M Disley, CEO of Horizon Discovery, commented: "We
are delighted to have completed the transformational acquisition of
Dharmacon and look forward to working closely with our new
colleagues and providing an expanded array of research solutions to
a cumulative customer base now exceeding 10,000 in number.
Dharmacon is a global leader in gene modulation products with a
fast growing gene-editing product portfolio which are highly
complementary to the gene editing, translational genomics,
personalised medicine, cell and gene therapy products and services
of Horizon. The combined business creates a global leader in the
application of gene modulation and gene editing technologies - two
rapidly growing and important areas of life science research.
"We expect the strong commercial synergies in markets, sales
channels, and brand strength to accelerate revenue growth and
margin expansion for the product portfolios of the enlarged
business, with additional opportunities to realise operational
efficiencies that are intended to drive significant cost savings
and EBITDA expansion as we continue to scale.
"The placing of GBP80 million was significantly oversubscribed
and we were pleased that both existing and new UK investors
strongly supported the acquisition. Furthermore Horizon is
delighted to welcome a significant number of new blue-chip
international shareholders including GE Healthcare and many
specialist US healthcare investors to the shareholder
register."
Following admission of the Consideration Shares, the Company's
issued share capital will comprise 148,915,950 ordinary shares of 1
pence each, with voting rights. Horizon does not hold any shares in
treasury. This figure of 148,915,950 ordinary shares may be used by
shareholders in Horizon to determine if they are required to notify
their interest in, or a change in their interest in, Horizon under
the Financial Conduct Authority's Disclosure and Transparency
Rules.
ENDS
For further information from Horizon Discovery Group plc, please
contact:
Horizon Discovery Group plc
Darrin Disley, Chief Executive Officer
Richard Vellacott, Chief Financial Officer
Chris Claxton, VP Investor Relations
Tel: +44 (0) 1223 655 580
Numis Securities Limited (Broker and NOMAD)
Michael Meade / Freddie Barnfield
Tel: +44 (0) 207 260 1000
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott / Susan Stuart / Matthew Neal / Melissa
Gardiner
Tel: +44 (0) 20 3709 5701
Email: horizon@consilium-comms.com
About Horizon Discovery Group plc - see
www.horizondiscovery.com
Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a world
leader in gene editing and gene modulation technologies. Horizon
designs and engineers cells using its translational genomics
platform, a highly precise and flexible suite of DNA editing tools
(rAAV, ZFN, CRISPR and Transposon) and, following the acquisition
of Dharmacon, its functional genomics platform comprising gene
knockdown (RNAi) and gene expression (cDNA, ORF) tools, for
research and clinical applications that advance human health.
Horizon's platforms and capabilities enable researchers to alter
almost any gene or modulate its function in human or mammalian
cell-lines.
Horizon offers an extensive range of catalogue products and
related research services to support a greater understanding of the
function of genes across all species and the genetic drivers of
human disease and the development of personalised molecular, cell
and gene therapies. These have been adopted by over 10,000
academic, drug discovery, drug manufacturing and clinical
diagnostics customers around the globe, as well as in the Company's
own R&D pipeline.
Horizon is headquartered in Cambridge, UK, and is listed on the
London Stock Exchange's AIM market under the ticker "HZD".
This information is provided by RNS
The company news service from the London Stock Exchange
END
ACQLLFFSTLILVID
(END) Dow Jones Newswires
August 31, 2017 10:30 ET (14:30 GMT)
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From Apr 2024 to May 2024
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From May 2023 to May 2024